Public Market Listing
1801HKEX
Live quotes, historical charts, and market capitalization for Innovent Biologics are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(13 total)
13Total Assets
0Approved
9Phase 3 / Filed
4Phase 1–2 / Early
9Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | BCMACell therapy | Multiple Myeloma | |
| Phase 3 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | GPRC5D x BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 3 | VEGFMonoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | PD-1 x IL-2Rα (IL2RA)Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | GLP-1/glucagon receptor (dual)Peptide | ObesityType 2 Diabetes | |
| Phase 3 | IL-23 p19Monoclonal antibody | Inflammatory Bowel DiseasePsoriasis Ulcerative Colitis | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
Tafolecimab(Sintbilo) | Phase 3 | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease |
| Phase 2 | Angiotensinogen (AGT)RNA / oligonucleotide | Hypertension | |
| Phase 2 | OX40LMonoclonal antibody | Atopic Dermatitis | |
| Phase 1 | GLP-1 receptorSmall molecule | Obesity | |
| Phase 1 | Undisclosed / early pipeline | Atopic Dermatitis |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.